Save 20% on All Global Market Reports With Code ONLINE20 – Gain Insights Into Tariffs, Inflation, and Industry Trends
What Is the Current Market Size and Growth Rate of the Cephalosporin Drugs Market?
The cephalosporin drugs market size has grown steadily in recent years. It will grow from $16.56 billion in 2024 to $17.17 billion in 2025 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to increasing prevalence of bacterial infections, growing antibiotic resistance, increasing healthcare expenditures, and rising demand for generics.
The cephalosporin drugs market size is expected to see steady growth in the next few years. It will grow to $20.18 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing geriatric population, rising awareness about bacterial infections, increasing number of hospital admissions, and growing development of new cephalosporin formulations. Major trends in forecast period include advancements in drug formulation technologies, technological integration in manufacturing processes, development of novel cephalosporin derivatives, and technological advancements in drug delivery systems.
Claim your free report sample now:
What Are the Key Drivers of the Cephalosporin Drugs Market?
The growing prevalence of infectious diseases is expected to propel the growth of the cephalosporin drugs market going forward. Infectious diseases are illnesses caused by microorganisms such as bacteria, viruses, fungi, or parasites that can spread from one individual to another. The increase in infectious diseases is due to the rise of antimicrobial resistance, which makes previously treatable infections more challenging to cure, leading to more widespread and persistent diseases. Cephalosporin drugs help treat infectious diseases, offering broad-spectrum antibacterial action, making them effective against various bacterial infections. They reduce treatment time by providing fast and reliable relief, improving patient outcomes. For instance, in November 2023, according to the Department of Health and Human Services, a US-based government department, the newly reported chronic hepatitis B (a viral infection that affects the liver and can lead to both acute and chronic disease) cases rose by 11% in 2022 compared to 2021. Therefore, the growing prevalence of infectious diseases is driving the growth of the cephalosporin drugs market.
How Is the Cephalosporin Drugs Market Segmented?
The cephalosporin drugs market covered in this report is segmented –
1) By Generation: First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation
2) By Route of Administration: Oral, Parenteral, Topical
3) By Application: Skin Infection, Respiratory Tract Infection, Urinary Tract Infection
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By First Generation: Cefazolin, Cephradine, Cephalexin
2) By Second Generation: Cefuroxime, Loracarbef, Cefaclor, Cefprozil
3) By Third Generation: Ceftriaxone, Cefdinir, Cefotaxime, Ceftazidime
4) By Fourth Generation: Cefepime, Cefpirome
5) By Fifth Generation: Ceftaroline, Ceftobiprole
How Are Current Trends Influencing the Cephalosporin Drugs Market Growth?
Major companies operating in the cephalosporin drugs market are focusing on developing innovative solutions, such as gram-negative bacterial infection treatment, to combat antimicrobial resistance and address the rising prevalence of drug-resistant infections globally. Gram-negative bacterial infection treatment refers to using targeted antibiotics to eliminate gram-negative bacteria, which have a unique cell wall structure that makes them more resistant to many standard antibiotics. For instance, in May 2024, Shionogi & Co. Ltd., a Japan-based pharmaceutical company, launched FETROJA (Cefiderocol). It is a novel antibiotic designed to treat serious gram-negative bacterial infections, including those resistant to other drugs. Its unique Trojan horse mechanism allows it to overcome multiple resistance barriers, offering a crucial option for patients with limited treatment choices.
Which Are the Top Companies in the Cephalosporin Drugs Market?
Major companies operating in the cephalosporin drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Baxter International, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Mankind Pharma Limited, Aristo Pharmaceuticals Ltd, Hetero Drugs Ltd, Covalent Laboratories Private Limited.
Get the full cephalosporin drugs market report here:
Which Region Is Projected to Account for the Largest Share of the Cephalosporin Drugs Market?
North America was the largest region in the cephalosporin drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cephalosporin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment